What is the maximum dose of orally disintegrating tablet (ODT) olanzapine for a 9‑year‑old child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maximum Olanzapine ODT Dose for a 9-Year-Old

For a 9-year-old child requiring acute behavioral management, olanzapine ODT can be dosed at 2.5 mg orally, with the option to repeat every 30–45 minutes up to a maximum of 30 mg daily, though pediatric experience is extremely limited and adverse effects are common at these doses. 1

Acute Agitation Dosing (Emergency/Inpatient Setting)

The American Academy of Pediatrics guideline for acute mental health emergencies in children provides the following framework for olanzapine use: 1

  • Initial dose: 2.5 mg PO/ODT for prepubertal children (ages 6–12 years) 1
  • Repeat dosing: May repeat every 30–45 minutes as needed 1
  • Maximum daily dose: 30 mg per day 1
  • Onset: 20–30 minutes for oral formulations 1
  • Peak effect: 45–60 minutes 1
  • Duration: 6–8 hours 1

The ODT formulation disintegrates rapidly (mean 15.78 seconds to initial disintegration, 0.97 minutes to complete disintegration) and is well-tolerated in terms of acceptability. 2

Chronic/Maintenance Dosing (Outpatient Setting)

For ongoing treatment beyond acute management, limited pediatric data exists:

  • Weight-based dosing: 0.12–0.29 mg/kg/day has been studied in children ages 6–11 years 3
  • Absolute dose range: 2.5–10 mg/day in preadolescent children 3
  • Mean dose studied: 7.5 mg/day (range 2.5–10 mg/day) 3

For a typical 9-year-old weighing approximately 30 kg, this translates to roughly 3.6–8.7 mg/day based on weight, though the absolute maximum studied was 10 mg/day in this age group. 3

Critical Safety Considerations

All five preadolescent children (ages 6–11) in one open-label trial discontinued olanzapine within 6 weeks due to adverse effects or lack of efficacy, highlighting significant tolerability concerns in this age group: 3

  • Sedation occurred in 60% of children 3
  • Weight gain up to 16 pounds occurred in 60% 3
  • Akathisia occurred in 40% 3
  • Psychotic symptoms did not respond in children with overt hallucinations 3

An 18-month-old who ingested 30–40 mg experienced significant respiratory distress and mental status changes, requiring close monitoring. 4 This underscores the need for careful dose titration and monitoring in younger patients.

Practical Dosing Algorithm

For a 9-year-old requiring olanzapine:

  1. Start low: Begin with 2.5 mg ODT 1, 3
  2. Titrate slowly: In acute settings, may repeat every 30–45 minutes up to 30 mg/day maximum 1
  3. Monitor closely: Watch for sedation, weight gain, and extrapyramidal symptoms after each dose 3
  4. Reassess frequently: If no improvement after appropriate dosing over one month in chronic use, discontinue 5 (extrapolated from methylphenidate monitoring principles)
  5. Consider alternatives: Given poor tolerability in preadolescents, other agents (risperidone, haloperidol with diphenhydramine) may be preferable 1

Comparison to Adolescent Dosing

Pharmacokinetic data in adolescents (ages 10–18) suggests that 5–10 mg once daily with a target of 10 mg/day is appropriate for most adolescent patients, with clearance and half-life similar to nonsmoking adults. 6 However, a 9-year-old prepubertal child should be dosed at the lower end of the pediatric range (2.5–5 mg) rather than using adolescent dosing. 1, 3

The maximum safe dose for a 9-year-old in acute settings is 30 mg/day per American Academy of Pediatrics guidelines, but expect significant adverse effects and consider this an absolute ceiling rather than a target. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Open-label olanzapine treatment in five preadolescent children.

Journal of child and adolescent psychopharmacology, 1998

Research

Olanzapine overdose in an 18-month-old child.

Journal of child and adolescent psychopharmacology, 1999

Guideline

Initiating Methylphenidate Therapy in Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.